GSK/XenoPort Prep RLS Candidate For Phase III In Neuropathic Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms plan to initiate pivotal trials of XP13512 in neuropathic pain this year after releasing positive Phase III data for restless legs syndrome.